2024
Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer
Sundaresan V, Wang R, Long J, Sprenkle P, Seibert T, Loeb S, Cooperberg M, Catalona W, Ma X, Gross C, Leapman M. Associations Between Prostate Magnetic Resonance Imaging, Genomic Testing, and Treatment for Localized Prostate Cancer. Urology Practice 2024, 11: 965-973. PMID: 39196719, DOI: 10.1097/upj.0000000000000679.Peer-Reviewed Original ResearchLocalized prostate cancerClinically localized prostate cancerHigh-risk diseaseProstate MRIProstate cancerTreatment intensificationIntensified treatmentGenomic testingTreated patientsProstate magnetic resonance imagingEnd Results databaseLong-term patient outcomesProstate cancer prognosisRetrospective cohort studyAssociated with decreased oddsRisk stratification toolPrimary study outcomeAssociated with increased oddsMagnetic resonance imagingResults databaseStratification toolTreatment patientsCohort studyRisk strataCancer prognosisHigh ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study
Rogne T, Wang R, Wang P, Deziel N, Metayer C, Wiemels J, Chen K, Warren J, Ma X. High ambient temperature in pregnancy and risk of childhood acute lymphoblastic leukaemia: an observational study. The Lancet Planetary Health 2024, 8: e506-e514. PMID: 38969477, PMCID: PMC11260908, DOI: 10.1016/s2542-5196(24)00121-9.Peer-Reviewed Original ResearchConceptsRisk of childhood acute lymphoblastic leukemiaChildhood acute lymphoblastic leukemiaAcute lymphoblastic leukemiaLymphoblastic leukemiaLatino childrenNon-Latino white childrenAssociated with risk of adverse pregnancy outcomesCalifornia Cancer RegistryRisk of acute lymphoblastic leukemiaCalifornia birth recordsRisk of adverse pregnancy outcomesPre-pregnancy periodAssociated with riskBayesian meta-regressionNational Institutes of HealthCancer RegistryCases of childhood acute lymphoblastic leukemiaNational Center for Advancing Translational SciencesAdverse pregnancy outcomesAcute lymphoblastic leukemia casesInstitutes of HealthInvestigation of mechanistic pathwaysBirth recordsGestational weeks 8Pre-pregnancyRacial differences in treatment and survival among older patients with multiple myeloma
Wang R, Neparidze N, Ma X, Colditz G, Chang S, Wang S. Racial differences in treatment and survival among older patients with multiple myeloma. Cancer Medicine 2024, 13: e6915. PMID: 38234237, PMCID: PMC10905251, DOI: 10.1002/cam4.6915.Peer-Reviewed Original ResearchNon-Hispanic whitesNon-Hispanic white patientsMultiple myelomaRacial differencesHazard ratioReceipt of treatmentOlder patientsIncreasing racial disparitiesIntroduction of novel agentsCox proportional hazards modelsMultivariate Cox proportional hazards modelLower mortalityStudy investigated racial differencesAssess survival outcomesProportional hazards modelNon-HispanicProportion of patientsMedicare beneficiariesRacial disparitiesTreatment utilizationHazards modelSurvival outcomesNovel agentsMM survivalMM treatment
2023
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupOlder patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
Shallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023, 7: 3213-3224. PMID: 36939371, PMCID: PMC10338212, DOI: 10.1182/bloodadvances.2022009074.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTKI adherenceTKI initiationOlder patientsMyeloid leukemiaEnd Results-Medicare databaseTyrosine kinase inhibitor usePolymerase chain reaction testingQuantitative polymerase chain reaction testingOlder patient populationCare of patientsHealth care accessReal-world studyReal-world evidenceLow socioeconomic statusLow-income subsidyFirst yearInfluenza vaccinationInhibitor useWorse survivalTKI treatmentMultivariable analysisPatient populationOptimal monitoringCare accessAssociation between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015
Cote D, Wang R, Morimoto L, Metayer C, Zada G, Wiemels J, Ma X. Association between birth characteristics and incidence of pituitary adenoma and craniopharyngioma: a registry-based study in California, 2001–2015. Cancer Causes & Control 2023, 34: 757-768. PMID: 37225897, PMCID: PMC10363066, DOI: 10.1007/s10552-023-01718-7.Peer-Reviewed Original ResearchConceptsOlder maternal ageMultivariable logistic regressionNon-Hispanic white individualsHigher maternal educationPituitary adenomasBirth characteristicsMaternal educationSignificant associationMaternal ageOdds ratioNon-Hispanic white raceUnconditional multivariable logistic regressionLogistic regressionParental sociodemographic characteristicsRegistry-based studyPopulation-based studyWhite individualsAdjusted odds ratioEarly-onset cancersNon-Hispanic whitesBirth pluralityIncident casesBlack raceFemale sexHispanic ethnicitySecond malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea
Wang R, Shallis R, Stempel JM, Huntington SF, Zeidan AM, Gore SD, Ma X, Podoltsev NA. Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. Blood Advances 2023, 7: 734-743. PMID: 35917456, PMCID: PMC9989521, DOI: 10.1182/bloodadvances.2022008259.Peer-Reviewed Original ResearchConceptsSecond malignanciesAcute myeloid leukemiaOlder patientsMyelodysplastic syndromeMyeloproliferative neoplasmsHU usersHigh riskPolycythemia veraEssential thrombocythemiaRisk of SMAML/myelodysplastic syndromeClassical Philadelphia chromosome-negative myeloproliferative neoplasmsImpact of hydroxyureaRetrospective cohort studyUse of hydroxyureaPhiladelphia chromosome-negative myeloproliferative neoplasmsClassical myeloproliferative neoplasmsCumulative incidence probabilityCohort studyCytoreductive therapyPatient characteristicsMedian ageHU useMyeloid leukemiaSecondary myelofibrosisUse of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation
Leapman M, Wang R, Loeb S, Seibert T, Gaylis F, Lowentritt B, Brown G, Chen R, Lin D, Witte J, Cooperberg M, Catalona W, Gross C, Ma X. Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Journal Of Urology 2023, 209: 710-718. PMID: 36753746, DOI: 10.1097/ju.0000000000003159.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerMixed-effects Poisson regressionPSA testingProstate biopsyProstate cancerEffects Poisson regressionMedicare beneficiariesPoisson regressionAdditional prostate biopsyRetrospective cohort studyProstate MRILocalized prostate cancerRepeat prostate biopsyRate of biopsyRace/ethnicityCensus tract povertyMedian followCohort studyMedian ageMonitoring testsProvider factorsPSA testClinical riskBiopsySociodemographic factorsTreatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023, 108: 2218-2223. PMID: 36655436, PMCID: PMC10388284, DOI: 10.3324/haematol.2022.282252.Peer-Reviewed Original ResearchOutdoor artificial light at night, air pollution, and risk of childhood acute lymphoblastic leukemia in the California Linkage Study of Early-Onset Cancers
Zhong C, Wang R, Morimoto L, Longcore T, Franklin M, Rogne T, Metayer C, Wiemels J, Ma X. Outdoor artificial light at night, air pollution, and risk of childhood acute lymphoblastic leukemia in the California Linkage Study of Early-Onset Cancers. Scientific Reports 2023, 13: 583. PMID: 36631468, PMCID: PMC9834257, DOI: 10.1038/s41598-022-23682-z.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaRisk of childhoodEarly-onset cancersLymphoblastic leukemiaBirth recordsChildhood acute lymphoblastic leukemiaNon-Hispanic white childrenHispanic childrenCalifornia Cancer RegistryEtiology of childhoodOutdoor artificial lightOutdoor ALANHighest tertileCancer RegistryLinkage studiesRisk factorsBorderline associationElevated riskCancer diagnosisCancerEnvironmental exposuresWhite childrenCommon typeAir pollutionRisk
2022
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period
Neparidze N, Wang R, Zeidan AM, Podoltsev NA, Shallis RM, Ma X, Davidoff AJ, Huntington SF. Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 2022, 36: 2136-2139. PMID: 35761025, PMCID: PMC9243711, DOI: 10.1038/s41375-022-01633-x.Peer-Reviewed Original ResearchInteraction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL
Feng Q, Zhou M, Li S, Morimoto L, Hansen H, Myint SS, Wang R, Metayer C, Kang A, Fear AL, Pappas D, Erlich H, Hollenbach JA, Mancuso N, Trachtenberg E, de Smith AJ, Ma X, Wiemels JL. Interaction between maternal killer immunoglobulin-like receptors and offspring HLAs and susceptibility of childhood ALL. Blood Advances 2022, 6: 3756-3766. PMID: 35500222, PMCID: PMC9631572, DOI: 10.1182/bloodadvances.2021006821.Peer-Reviewed Original ResearchConceptsKiller immunoglobulin-like receptorsMaternal killer immunoglobulin-like receptorsAcute lymphoblastic leukemiaChild-mother pairsImmunoglobulin-like receptorsArginase IIKIR interactionsLower riskNon-Latino white subjectsLower tumor necrosisCase-control studyEtiology of childhoodDevelopment of childhoodHLA-KIRNeonatal cytokinesCytokine levelsCytokine profileLymphoblastic leukemiaImmune factorsImmune phenotypeTumor necrosisHigh riskChildhood leukemiaCytokine controlSignificant associationHispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study
Graham C, Metayer C, Morimoto LM, Wiemels JL, Siddique A, Di M, Rodwin RL, Kadan-Lottick NS, Ma X, Wang R. Hispanic Ethnicity Differences in Birth Characteristics, Maternal Birthplace, and Risk of Early-Onset Hodgkin Lymphoma: A Population-Based Case–Control Study. Cancer Epidemiology Biomarkers & Prevention 2022, 31: 1788-1795. PMID: 35709749, PMCID: PMC9444874, DOI: 10.1158/1055-9965.epi-22-0335.Peer-Reviewed Original ResearchConceptsNon-Hispanic whitesHodgkin's lymphomaCase-control studyBirth characteristicsMaternal birthplaceMaternal agePopulation-based case-control studyMultivariable logistic regression modelConfidence intervalsEthnic differencesEarly-onset cancersPotential ethnic differencesForeign-born mothersLogistic regression modelsEthnicity differencesRace/ethnicityYear of birthLymphomaPaternal ageFemale HispanicsHispanic casesMale HispanicsHodgkinAgeRiskSurvival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
Di M, Cui C, Kothari S, Zeidan AM, Podoltsev NA, Neparidze N, Shallis R, Wang R, Ma X, Huntington SF. Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood Advances 2022, 6: 3339-3342. PMID: 35240689, PMCID: PMC9198937, DOI: 10.1182/bloodadvances.2021006934.Peer-Reviewed Original ResearchCytomegalovirus proteins, maternal pregnancy cytokines, and their impact on neonatal immune cytokine profiles and acute lymphoblastic leukemogenesis in children.
Wiemels JL, Wang R, Zhou M, Hansen H, Gallant R, Jung J, Mancuso N, De Smith AJ, Metayer C, Kogan SC, Ma X. Cytomegalovirus proteins, maternal pregnancy cytokines, and their impact on neonatal immune cytokine profiles and acute lymphoblastic leukemogenesis in children. Haematologica 2022, 107: 2266-2270. PMID: 35638549, PMCID: PMC9425315, DOI: 10.3324/haematol.2022.280826.Peer-Reviewed Original ResearchMicroangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study
Lam R, Tarangelo N, Wang R, Horibe M, Grimshaw AA, Jain D, Haffar S, Bazerbachi F, Kunz PL, Li DK. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. The Oncologist 2022, 27: 751-759. PMID: 35589098, PMCID: PMC9438916, DOI: 10.1093/oncolo/oyac093.Peer-Reviewed Original ResearchConceptsGastric signet ring cell carcinomaSignet ring cell carcinomaMicroangiopathic hemolytic anemiaHemolytic anemiaCell carcinomaMultivariable Cox proportional hazards regression modelingCox proportional hazards regression modelingSystematic reviewRare paraneoplastic syndromeStage-matched casesEnd Results (SEER) databaseLate-stage complicationsRisk of mortalityCase-control studyBone painParaneoplastic syndromeFatal complicationMedian survivalMetastatic diseaseOverall survivalLymph nodesIndex presentationPrognostic featuresResults databasePooled cohortPhysical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia
Rodwin RL, Ma X, Ness KK, Kadan-Lottick NS, Wang R. Physical Therapy Utilization Among Hospitalized Patients With Pediatric Acute Lymphoblastic Leukemia. JCO Oncology Practice 2022, 18: e1060-e1068. PMID: 35427182, PMCID: PMC9287366, DOI: 10.1200/op.21.00796.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaPediatric acute lymphoblastic leukemiaPhysical therapyPhysical functionLymphoblastic leukemiaNeuromuscular conditionsImpaired physical functionPhysical therapy utilizationPremier Healthcare DatabasePediatric hematologists/oncologistsEarly physical therapyInpatient physical therapyHematologists/oncologistsLong-term healthCohort studyFirst hospitalizationMultivariable analysisTherapy utilizationClinical variablesTeaching hospitalHealthcare databasesPatientsAddress disparitiesHospitalAge 10The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis
Goksu SY, Ozer M, Goksu BB, Wang R, Khatib J, Patel PA, Vusirikala M, Cole S, Seyhanli A, Collins RH, Chung S, Zeidan AM, Madanat YF. The impact of race and ethnicity on outcomes of patients with myelodysplastic syndromes: a population-based analysis. Leukemia & Lymphoma 2022, 63: 1651-1659. PMID: 35133215, DOI: 10.1080/10428194.2022.2032034.Peer-Reviewed Original ResearchConceptsIncidence rate ratiosNon-Hispanic whitesMyelodysplastic syndromeRace/ethnicityNHB patientsNon-Hispanic blacksSurvival outcomesDisease characteristicsAge groupsHigher incidence rate ratioLower incidence rate ratiosOutcomes of patientsBetter overall survivalPopulation-based analysisAcute myeloid leukemiaNHW patientsAdult patientsOverall survivalSEER databaseClinical outcomesIncidence rateMyeloid leukemiaPatientsEthnic backgroundDisease riskPractice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
Bewersdorf JP, Prozora S, Podoltsev NA, Shallis R, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.Peer-Reviewed Original ResearchConceptsAcute promyelocytic leukemiaAdverse outcomesPromyelocytic leukemiaNational Comprehensive Cancer Network guidelinesBaseline white blood cell countFavorable long-term prognosisWhite blood cell countVizient Clinical Data BaseGuideline-concordant regimensGuideline-concordant therapyGuideline-concordant treatmentGuideline-recommended therapiesBaseline clinical characteristicsHigh-risk diseaseLong-term prognosisPopulation-based registryBlood cell countClinical data baseLarge database analysisLogistic regression modelsTreatment concordanceClinical characteristicsReal-world practiceTreatment patternsNetwork guidelinesChanges in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates